Genesis Healthcare is now at the disclosure-statement stage, seeking authority to solicit votes on an amended plan built around a sale of substantially all assets and a subsequent liquidation, with a reorganization toggle if the asset purchase agreement is terminated. The company and 298 affiliates entered Chapter 11 on July 9, 2025, after COVID-era disruption, staffing inflation, inadequate reimbursement and legacy liabilities—including roughly $8 million per month of personal-injury and wrongful-death defense and settlement costs—overwhelmed liquidity despite prior capital support, as described in the first-day declarationDkt. 18. The facilities identified so far account for approximately $1.05 billion of funded obligations spanning ABL debt, term loans, unsecured notes and subordinated notes; that figure is an identified subtotal, not a complete funded-debt total.
Genesis began the case pursuing a section 363 process with ReGen affiliates as stalking-horse bidder and obtained interim authority for a $30 million junior DIP facility, including $12 million of initial availability, plus use of cash collateral under the interim financing orderDkt. 57. The process quickly became contested: the unsecured-creditors committee sought more time to evaluate alternative financing and test the insider-backed transaction, arguing that the stalking-horse agreement had been filed late and that the proposed timetable could suppress competition in its adjournment motionDkt. 478. By February 2026, the debtors sought to refinance and extend their postpetition liquidity through an $80 million facility, with up to $25 million of additional availability tied to the Bold Quail settlement, under the amend-and-extend DIP motionDkt. 2356.
The case has since moved from the original stalking-horse framework to a plan-centered exit. The debtors say the amended disclosure statement now includes a liquidation analysis, sources and uses, a general-unsecured-creditor distribution model and additional risk disclosure; their proposed plan would implement the sale-and-liquidation transaction unless the restructuring toggle is activated, according to the disclosure-statement replyDkt. 3072. The unsecured-creditors committee supports sending the plan to creditors and says the current sale transaction delivers approximately $225 million more value than the initial insider bid, with the DIP obligations expected to be paid in full, as set out in its supporting statementDkt. 3073. The immediate milestone is the July 31, 2026 disclosure-statement hearing at 9:30 a.m. Central, where approval of the disclosure statement and solicitation procedures is going forward under the amended hearing agendaDkt. 3075.
